New "me-too" beta blocker dissed by experts

The Wall Street Journal health blog pokes fun at Bystolic, the newly approved beta blocker from Forest Laboratories and Mylan Laboratories, as the ultimate "me-too" drug. It's number 19 in the list of beta blockers now available in the U.S. The developers counter by saying that the drug has "placebo-like" side effects, making compliance easier. One Mayo Clinic expert cautions the numbers are coming from small studies, and with Glaxo's Coreg going generic, he's going with the lower cost drug.

- read the blog item

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.